宫颈癌三维近距离治疗中两种常用施源器的剂量学比较

目的 对比研究环形施源器(Nucletron#090.617)和三管施源器(Nucletron#189.730)对宫颈癌患者三维近距离治疗受照剂量的影响。 方法 选取已完成治疗的根治性宫颈癌Ⅱ_B—Ⅳ_A期患者 40例,20例采用环形施源器,另外 20例采用三管施源器,分别统计三维近距离治疗计划中靶区 V_150% 、D₁₀₀和膀胱、直肠、小肠 D_{2 cc}。采用立独样本t检验方法对比分析两种施源器在宫颈癌三维近距离治疗中CTV和OAR的剂量。 结果 环形施源器和三管施源器的靶体积分别为(66.04±13.86) cm³、(65.67±15.08) cm³(P=0.052)。环形施源器中 D₁₀₀、V_150%分别为(3.71±0.34) Gy、0.54±0.02;三管施源器中 D₁₀₀、V_150%分别为(3.37±0.49) Gy、0.56±0.04(P=0.016、0.034)。环形施源器中膀胱、直肠、小肠 D_{2 cc}分别为(4.33±0.39)、(3.38±0.30)、(3.04±1.02) Gy,三管施源器的分别为(2.93±1.27)、(2.95±0.80)、(3.41±0.57) Gy (P=0.000、0.037、0.171)。 结论 宫颈癌三维近距离治疗中环形施源器靶区的覆盖度优于三管施源器,而膀胱、直肠受量同时也高于三管施源器,但小肠受量无差异。临床治疗中主要还是根据肿瘤的位置、侵犯范围以及阴道的条件来选择施源器。

Dosimetric comparison between two brachytherapy applicators in cervical cancer treatment

Objective To compare the dosimetric parameters between the use of Tandem and Ring (TR;Nucletron#090.617) or Tandem and Ovoid (TO;Nucletron#189.730) applicators during three-dimensional (3D) high-dose rate (HDR) brachytherapy (BT) for cervical cancer.Methods The records of 40 cervical cancer (ⅡB-ⅣA) patients treated with 3D-image-guided HDR-BT were reviewed.Of these 40 patients, 20 were treated with the TO applicator, and 20 with the TR applicator.The D100% and V150% of the clinical target volume (CTV) and the D2 cc of organs at risk (OAR)(the rectum, bladder, and small intestine) during 3D-HDR-BT using TO and TR were compared using the independent sample t-test.ResultsOverall metrics:CTV volume:66.04±13.86 cm3(TR) vs.65.67±15.08 cm3(TO)(P=0.052);CTV D100:3.71±0.34 Gy (TR) vs.3.37±0.49 Gy (TO)(P=0.016);CTV V150%:0.54±0.02(TR) vs.0.56±0.04(TO)(P=0.034);rectum D2 cc:3.38±0.30 Gy (TR) vs.2.95±0.80 Gy (TO)P=0.037);bladder D2 cc:4.33±0.39 Gy (TR) vs.2.93±1.27 Gy (TO)(P=0.00);and small ntestine D2 cc:3.04±1.02 Gy (TR) vs.3.41±0.57 Gy (TO)(P=0.171).Conclusions TR has better CTV coverage than TO during 3D HDR brachytherapy for cervical cancer.In addition, D2 cc of the rectum and bladder were both igher with TR than with TO, though there is no significant dosimetric difference in the small intestine between the two applicators.Therefore, tumor location, extent of invasion, and vaginal conditions should be considered when selecting the suitable pplicator for the treatment of cervical cancer.